Ricardo Anaya, President of the opposition National Action Party, has called for the pharmaceutical sector in Mexico to be opened to greater competition in order to reduce the price of medication. He added that the party will propose two actions: the first, to strengthen the powers of the Federal Competition Commission (COFECE), and second, to pressure authorities to “tighten their grip” against abuses, hoping to stop the rising costs of healthcare and medication.
“Medicine prices are through the roof. For example: an antibiotic that cost 92 pesos three years ago now costs twice as much. Drugs for diabetes, cold medicines, painkillers and stomach aids have risen by more than 50%” he said.
The PAN’s national leader pointed to Mexico’s high concentration in the medicine industry for the situation which, along with a lack of competition, allows pharmaceutical companies to raise prices, knowing they face few competitors for their products. “It’s been enough of having a few take advantage of the many. We’re not discovering anything new, this is something countries around the world have done. We demand cheaper medicines and greater competition.”
Full content: Vanguardia
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Belgian Authorities Detain Multiple Individuals Over Alleged Huawei Bribery in EU Parliament
Mar 13, 2025 by
CPI
Grubhub’s Antitrust Case to Proceed in Federal Court, Second Circuit Rules
Mar 13, 2025 by
CPI
Pharma Giants Mallinckrodt and Endo to Merge in Multi-Billion-Dollar Deal
Mar 13, 2025 by
CPI
FTC Targets Meta’s Market Power, Calls Zuckerberg to Testify
Mar 13, 2025 by
CPI
French Watchdog Approves Carrefour’s Expansion, Orders Store Sell-Off
Mar 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li